ORGANIZATION

TPP Hoped to Set Standard for Global IP Protection Rules: PhRMA Japan Rep. Wolf

February 25, 2013
The Trans-Pacific Partnership (TPP) free trade pact, pushed by US President Barack Obama, is meaningful for new drug development of pharmaceutical companies, since it will likely lay the groundwork for globally standardized rules on intellectual property (IP) rights, says Ira…

To read the full story

ORGANIZATION

By Philip Carrigan

“The Tesla and SpaceX CEO sent an email to employees at both companies on Tuesday saying everyone must spend 40 hours per week in the office. ‘If you don’t show up, we will assume you have resigned. The more senior…

By Takashi Ohama

Pharma companies have seen Japan’s new “zero” premium coefficient rule extensively applied to medicines with low cost disclosure ratios since its introduction under the drug pricing reform this April. Of new drugs listed in the past two months, all six…

By Reiji Anasako

The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…

A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…